Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an "ex vivo" tacrolimus perfusion by Pratschke, Sebastian et al.
CLINICAL TRIAL PROTOCOL Open Access
Protocol TOP-Study (tacrolimus organ perfusion):
a prospective randomized multicenter trial to
reduce ischemia reperfusion injury in
transplantation of marginal liver grafts with an
ex vivo tacrolimus perfusion
Sebastian Pratschke
1, Michael Eder
1, Michael Heise
2, Silvio Nadalin
3, Andreas Pascher
4, Peter Schemmer
5,
Marcus N Scherer
6, Frank Ulrich
7, Heiner Wolters
8, Karl-Walter Jauch
1, Dirk Wöhling
9 and Martin K Angele
1*
Abstract
Background: Critical organ shortage results in the utilization of extended donor criteria (EDC) liver grafts. These
marginal liver grafts are prone to increased ischemia reperfusion injury (IRI) which may contribute to deteriorated
graft function and survival. Experimental data have shown that the calcineurin inhibitor tacrolimus exerts protective
effects on hepatic IRI when applied intravenously or directly as a hepatic rinse. Therefore, the aim of the present
study is to examine the effects of an ex vivo tacrolimus perfusion on IRI in transplantation of EDC liver grafts.
Methods/Design: The TOP-Study (tacrolimus organ perfusion) is a randomized multicenter trial comparing the
ex vivo tacrolimus perfusion of marginal liver grafts with placebo. We hypothesize that a tacrolimus rinse reduces
IRI, potentially improving organ survival following transplantation of EDC livers. The study includes livers with two
or more EDC, according to Eurotransplant International Foundation’s definition of EDC livers. Prior to implantation,
livers randomized to the treatment group are rinsed with tacrolimus at a concentration of 20 ng/ml in 1000 ml
Custodiol solution and in the placebo group with Custodiol alone. The primary endpoint is the maximum serum
alanine transamninase (ALT) level within the first 48 hours after surgery; however, the study design also includes a
1-year observation period following transplantation. The TOP-Study is an investigator-initiated trial sponsored by the
University of Munich Hospital. Seven other German transplant centers are participating (Berlin, Frankfurt, Heidelberg,
Mainz, Münster, Regensburg, Tübingen) and aim to include a total of 86 patients.
Discussion: Tacrolimus organ perfusion represents a promising strategy to reduce hepatic IRI following the
transplantation of marginal liver grafts. This treatment may help to improve the function of EDC grafts and
therefore safely expand the donor pool in light of critical organ shortage.
Trial register: EudraCT number: 2010-021333-31, ClinicalTrials.gov identifier: NCT01564095
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Graft function, Graft survival
* Correspondence: Martin.Angele@med.uni-muenchen.de
1Department of Surgery, University of Munich Hospital, Campus Grosshadern,
Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich,
Germany
Full list of author information is available at the end of the article
TRANSPLANTATION 
RESEARCH
© 2013 Pratschke et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Pratschke et al. Transplantation Research 2013, 2:3
http://www.transplantationresearch.com/content/2/1/3Introduction
Organ shortage represents a critical problem in trans-
plantation medicine. In 2010, 1192 liver transplantations
were performed in Germany as opposed to 1846 new en-
tries on the waiting list (German Organ Transplantation
Foundation (Deutsche Stiftung Organtransplantation,
DSO), Annual Report, 2010). As a consequence of this
discrepancy, there is a noticeable trend towards the
utilization of extended donor criteria (EDC) grafts. Data
provided by the Eurotransplant International Foundation
indicate that the proportion of liver grafts exhibiting one
or more EDC increased from 29% in 1997 to 73% in
2010 (Axel Rahmel, Medical Director, Eurotransplant,
personal communication). The proportion of grafts with
two or more EDC increased from 4% up to 28% over the
same time period.
Ischemia reperfusion injury (IRI) is a complex inflam-
matory, allogen-independent process commonly seen
following graft transplantation; however, it is particularly
pronounced in marginal organs [1-3], and may contrib-
ute to poor graft function and reduced survival in these
recipients [4,5]. During ischemia and reperfusion,
proinflammatory cytokines such as IL-6 or TNF-α are
released into the systemic circulation by Kupffer cells
and migrating neutrophils [6]. These molecules induce a
complex inflammatory cascade and trigger the gener-
ation of reactive oxygen species (ROS) thereby affecting
the redox status of the cell [7]. In turn, increased intra-
cellular levels of oxidized glutathione contribute to
impairment of the liver’s antioxidative defense system
[8]. In addition to sinusoidal congestion caused by
endothelial sticking of migrating neutrophils, an imbal-
ance between vasoconstrictive (endothelin-1) [9] and
vasodilatatory substances (NO) [10] may directly dis-
turb the hepatic microcirculation. This is considered to
be a central pathomechanism for organ dysfunction
and primary nonfunction [9,10], especially in marginal
liver grafts [11,12]. Besides poor graft quality, the recip-
ients’ health status (model for end-stage liver disease
(MELD) score) may also influence the outcome after
liver transplantation [13]. The combination of extended
criteria donors and poor recipient condition may be re-
sponsible for a reduction of graft survival following
liver transplantation. In 2011, the 5-year graft survival
rate in Germany was 52.6% compared to the inter-
national mean of 66.2% (data provided by DSO, Collab-
orative Transplant Study (CTS)).
Therefore, strategies must be developed to improve the
function and survival of EDC organs. Several experimental
models have shown that tacrolimus preconditioning be-
fore liver transplantation has protective effects (Table 1).
The authors have recently demonstrated that an ex vivo
tacrolimus flush reduces IRI in a model of experimental
liver transplantation in rats [14]. Based on these experi-
mental findings, a study protocol of a single ex vivo ta-
crolimus rinse prior to reperfusion in marginal livers
was developed (Trial register: EudraCT number: 2010-
021333-31, ClinicalTrials.gov identifier: NCT 01564095).
The aim of the TOP-Study (tacrolimus organ perfusion) is
to reduce hepatic IRI and improve long-term organ
survival following transplantation of marginal livers.
Hypothesis and endpoints
The hypothesis of the study is that a single ex vivo ta-
crolimus perfusion prior to reperfusion reduces IRI and
improves long-term graft survival. The primary end-
point is the maximum alanine transaminase (ALT) level
within the first 48 hours following liver transplantation.
Secondary endpoints are ALT and aspartate transamin-
ase (AST) levels, graft function (prothrombin time, bili-
rubin), and creatinine on days 1, 2, 4 and 7. In addition,
the study documents graft and patient survival, histo-
logically confirmed rejection, as well as ischemic-type
biliary lesions (ITBL).
Table 1 Tacrolimus and ischemia reperfusion injury experimental animal studies
Author Cold vs warm
ischemia
Ischemic time Species TAC-application: End points P
Systemic vs organ
rinse
Sakr et al., 1991 [15] Warm 45 minutes Rat Systemic Survival, aminotransferases, LDH <0.05
Kawano et al., 1995 [16] Warm 60 minutes Rat Systemic Microcirculation, aminotransferases <0.05
Kawano et al., 1996 [17] Cold 80 minutes Rat Systemic Lipid peroxidation, aminotransferases <0.05
Garcia-Criado et al., 1997 [18] Warm 90 minutes Rat Systemic Survival <0.01
ROS, cytokines, aminotransferases,
neutrophil infiltration
<0.05
Takeichi et al., 2009 [19] Warm 50 minutes Rat Systemic Aminotransferases, neutrophil activation <0.05
Huser et al., 2009 [20] Cold 120 minutes Rat Systemic Aminotransferases, histology 0.001
Pratschke et al., 2012 [14] Cold 24 hours Rat Organ rinse Aminotransferases, glutathione metabolism <0.05
LDH, lactate dehydrogenase; ROS, reactive oxygen species; TAC, tacrolimus.
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The TOP-Study is an investigator-initiated, prospective,
randomized trial comparing the ex vivo perfusion of
marginal livers with tacrolimus to placebo prior to trans-
plantation. The main inclusion criterion is the presence
of two or more EDC. IRI is assessed by serum ALT and
AST levels over a period of 7 days. Following this period,
organ and patient survival, bile duct complications, rejec-
tions and organ function are monitored for 1 year. The
TOP-Study is sponsored by the University of Munich
Hospital with financial support provided by a grant from
Astellas Pharma GmbH, München, Germany. Research
and organizational support is provided by the contract
research organisation (CRO) DABIO Gesellschaft für
Auftragsforschung mbH, Höhenkirchen, Germany.
Inclusion and exclusion criteria
The study includes patients undergoing liver transplant-
ation in the participating centers who meet the following
criteria: chronic terminal liver failure, over 18 years of
age, first liver transplantation, and informed, signed con-
sent by the recipient. Donor organs exhibiting two or
more EDC according to the Eurotransplant Manual for
extended criteria liver donors (Table 2) are included
[21].
Patients receiving split liver and multiorgan trans-
plantations are excluded as well as those undergoing
retransplantation, high urgency transplantation or pediatric
transplantation. In addition, recipients with extrahepatic
malignant diseases, and organs from donors with hepatitis
B or C infection, are excluded.
Perfusion procedure
Livers are perfused with 1000 ml of the rinse solution
from a height of 100 cm without additional pressure
using polyvinylchloride (PVC)-free infusion systems with
a 12 gauge cannula. The portal vein and the common
hepatic artery are flushed sequentially, with 500 ml each.
In the test arm, tacrolimus is added to 1000 ml
Custodiol histidine-tryptophan-ketoglutarate (HTK) so-
lution at a concentration of 20 ng/ml. A total of 20 μg
tacrolimus is applied. In the placebo group livers are
perfused with 1000 ml Custodiol. The perfusion proced-
ure is performed at the end of the back-table preparation
at least 1 hour before reperfusion. The duration of the
perfusion does not exceed 15 minutes (Figure 1). Prior
to reperfusion livers are flushed in situ with 500 ml of
the recipients’ blood.
Liver transplantation and postoperative
immunosuppressant regimen
Liver transplantation is performed according to the stand-
ard clinical practice at each center. Immunosuppression
during the first 7 postoperative days is tacrolimus-based.
Thereafter, a tacrolimus-based immunosuppressive regimen
is suggested but not mandatory. Additional immunosup-
pression, that is, corticoids, is administered at the discretion
of the treating clinician.
Follow-up
The present trial includes a 7-day interventional
study regulated by the German Pharmaceuticals Act
(Arzneimittelgesetz, AMG) and a non-interventional
study (NIS) over 1 year (Figure 2). During the entire study
period, the monitoring of safety and data is performed
according to Good Clinical Practice (GCP) guidelines.
Data management and CRO duties are performed by
the DABIO Gesellschaft für Auftragsforschung mbH,
Höhenkirchen, Germany.
Study visits
To characterize IRI and graft function serum ALT/AST,
prothrombin ratio and bilirubin are measured on postop-
erative days 1, 2, 4, 7, as well as 6 and 12 months following
liver transplantation (Figure 2). Moreover, graft and pa-
tient survival, bile duct complications and histologically
confirmed rejections are assessed.
Table 2 Extended donor criteria (EDC)
Criteria
Donor age >65 years
Macrovesicular steatosis >40% (macroscopy or biopsy)
BMI >30
Sodium >165 mmol/l
ICU stay and ventilation >7 days
Cold ischemia time >13 hours
AST >99 u/l
ALT >105 u/l
Bilirubin >3 mg/dl (>51 μmol/l)
Application of epinephrine
Criteria according to the Eurotransplant Manual for EDC in liver grafts [21].
BMI, body mass index; EDC, extended donor criteria; ICU, intensive care unit;
ALT, alanine transaminase; AST, aspartate transamianse.
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Figure 1 Flow chart of tacrolimus organ perfusion. EDC,
extended donor criteria; HTK, histidine-tryptophan-ketoglutarate.
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The primary endpoint of the study is the maximum
serum ALT level within 48 hours following liver trans-
plantation, which reflects the degree of acute hepatocel-
lular injury. Non-parametric analysis using Wilcoxon
rank-sum test is performed to compare the maximum
ALT levels in grafts treated with tacrolimus versus
placebo. Based on a previous study using non-marginal
healthy grafts, an effect size of approximately 0.5 was
calculated [22]. In experimental studies, therapies for the
treatment of IRI were more effective in steatotic livers
[23,24]. Since recipients of marginal organs are incorpo-
rated in the present study, the predicted improvement in
postoperative ALT levels should be higher than in non-
marginal grafts. Thus, an effect size of 0.7 was consid-
ered appropriate for the sample size calculation. The
power of the test is 80% at a significance level of 0.05.
Therefore, sample size estimation (nQuery Advisor 6.1,
Statistical Solutions, Saugus, MA, USA) for two un-
paired samples using the Wilcoxon rank-sum test with
an expected dropout rate of 15% results in an estimated
sample size of 86 (43 tacrolimus vs 43 placebo).
To homogenize the patient collective only marginal
organs with two or more EDC are included. Nonethe-
less, all EDC may affect the primary endpoint. Since
documentation of EDC is required for patient inclusion,
those parameters will be analyzed as potential con-
founders. Moreover, recipient age will also be registered.
Participating centers
The Departments of Surgery of the following German
university hospitals are participating in this trial: Charité
Campus Virchow-Klinikum, Berlin; Johann Wolfgang
Goethe-University, Frankfurt am Main; Johannes Gutenberg
University, Mainz; Westphalian Wilhelms-University,
Münster; Ruprecht-Karls-University, Heidelberg; University
of Regensburg; Eberhard Karls University, Tübingen; and
Campus Grosshadern, Ludwig-Maximilians-University,
Munich.
Ethics and safety
Protocol version 2.1 has been approved by the local ethic
committees of the ethics committee of the university of
Munich. The study complies with the Declaration of
Helsinki and GCP guidelines. Informed consent is
obtained from each patient in written form prior to
randomization. The patient is informed about the na-
ture, duration and possible consequences of the trial by
an investigator specifically registered for this trial.
Current status (October 2012)
Study permission by the Federal Institute for Drugs and
Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte, BfArM) was received on 29 July 2011
and ethics committee approval on 23 August 2011.
Version 2.1 of the protocol is active. To date (October
2012), seven centers (Berlin, Frankfurt, Heidelberg,
Mainz, Munich, Regensburg and Tübingen) have been
initiated and 17 patients have been recruited for the
study. Estimated closure for recruitment for the study
will be 31 December 2013. One year thereafter the study
will be closed. Data calculation will require 6 months. A
finalized report of the study is expected for July 2015.
Discussion
Organ shortage and the consecutive transplantation of
EDC grafts remain an unsolved problem in organ trans-
plantation. Marginal organs are increasingly accepted,
which is associated with increased acute IRI [4,23] and
diminished graft survival [5,25,26]. An increased suscep-
tibility of marginal organs to the pathomechanisms of
IRI is discussed as a potential cause for the impaired
outcome of these grafts [2,3]. Thus, clinically relevant
strategies must be developed to prevent IRI in marginal
organs.
Several experimental studies have demonstrated protect-
ive effects of tacrolimus on IRI following liver transplant-
ation [14,17,20]. Despite their promising results, these
models were based on systemic donor preconditioning,
which is logistically difficult to incorporate into clinical
practice due to the existing organ allocation practice in the
Eurotransplant zone.
An ex vivo tacrolimus treatment may represent a solu-
tion to this problem. Recent experimental data indicates
a protective effect of an ex vivo tacrolimus rinse in a
model of experimental liver transplantation in rats [14].
Preservation of intracellular glutathione levels was sug-
gested as a potential mechanism in this study. The
calcineurin inhibitor tacrolimus acts through a blockade
of the intracellular calcineurin-calmodulin complex. This
blockade inhibits the calcium-dependent phosphoryl-
ation of the nuclear factor of activated T cells (NFAT).
As a consequence, IL-2, which is normally involved in
the activation of CD4+ and CD8+ T cells, and the IL-2
receptor are downregulated. Thus, the inactivation of T
cells is regarded as the central mechanism in the im-
munosuppressant properties of tacrolimus [27,28].
TOP-Study Non interventional study
d=1 2     4  7 Discharge
from hospital
6 months
Liver 
transplantation
Ex vivo Tacrolimus
Perfusion
12 months
Donor Recipient
Figure 2 Study visits TOP-Study (tacrolimus organ perfusion).
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independent hepatic IRI, which is characterized by the
release of a complex cascade of cytokines including IL-6
and TNF-α, the generation of ROS, the accumulation
and transmigration of different cell types (that is, lym-
phocytes, neutrophils, platelets), as well as alterations of
the microcirculation potentially causing graft dysfunc-
tion or even non-function [6]. In this respect, T cells
have been shown to be critically involved in the induc-
tion of IRI of the liver [29-32]. A rapid recruitment of
CD4+ T cells in hepatic sinusoids as early as 30 minutes
after reperfusion is followed by their migration through
the endothelial barrier to injured hepatic tissue [30].
Although CD4+ T cells themselves are not cytotoxic,
they release a panel of cytokines, chemokines and adhe-
sion molecules which are potentially harmful to the
organ. Moreover, CD4+ T cells interact with platelets
and Kupffer cells which further aggravate IRI [33]. How-
ever, it has yet to be determined whether tacrolimus
affects IRI after liver transplantation via CD4+ T cells.
Neutrophils are also actively involved in hepatic IRI.
The accumulation of neutrophils congests hepatic sinu-
soids and leads to the release of proinflammatory cyto-
kines (that is, TNF-α and IL-6), as well as ROS [34].
Adhesion molecules such as P-selectin and ICAM-1 are
involved in the process of neutrophil recruitment [35].
The application of tacrolimus decreases the expression
of these adhesion molecules, thereby attenuating neutro-
phil recruitment [36,37]. In addition, direct suppressive
effects of tacrolimus on the activation of Kupffer cells,
which also release proinflammatory cytokines have been
demonstrated in vitro [38]. This anti-inflammatory effect
of tacrolimus was also evident in human liver biopsies
after the transplantation of organs rinsed with tacroli-
mus [39].
With respect to the microcirculation, direct effects of
tacrolimus on the expression of vasoconstrictive sub-
stances (endothelin-1) in endothelial cells have been
shown, which might further improve hepatic microcircu-
lation [40]. Increased levels of ROS are known to be in-
volved in the pathogenesis of IRI. The application of
tacrolimus in vivo is associated with a reduction of ROS
[18]. Recently, a rat model of liver transplantation dem-
onstrated that tacrolimus increases glutathione metabol-
ism, which in turn may protect organ function by reducing
ROS toxicity [14]. Tacrolimus has also been found to
exert anti-apoptotic effects by preventing Fas-induced
apoptosis in human hepatocytes in vitro [41], as well as
in an in vivo model of IRI in rats [42]. A decrease in
liver apoptosis may contribute to persisting protection
of cellular integrity. In summary, several potentially
s y n e r g i s t i cm e c h a n i s m sf o rt h ep r o t e c t i v ee f f e c t so ft a -
crolimus in the setting of ischemia-reperfusion injury
have been proposed.
Preliminary clinical data have shown beneficial results
of tacrolimus preconditioning in human liver transplant-
ation (Table 3). In addition, the tacrolimus rinse proced-
ure has been tested clinically in a phase I trial (Table 3).
In a previous trial, Peter et al. demonstrated a significant
reduction of aminotransferase levels following the trans-
plantation of normal livers rinsed with 20 ng/ml tacrolimus
[22]. Although the results of this trial were promising, the
clinical impact was limited by the small number of patients
included (n= 20). In a similar clinical study, Kristo et al.
recently failed to show a reduction in ALT levels on day 6
after transplantation [39]. However, the study population
was relatively small, and, as most patients received healthy
organs, the results cannot be directly compared to a study
of marginal grafts. Postoperative aminotransferase levels in
the Kristo et al. study were generally quite low, with serum
ALT levels in the control group reaching almost normal
levels 6 days after transplantation [39]. Nevertheless, the
authors showed an impressive reduction in precursors of
proinflammatory enzymes following tacrolimus rinse [39].
In the TOP-Study, livers are treated with a single
ex vivo tacrolimus rinse prior to implantation, with the
aim of reducing graft damage and secondarily improving
the long-term course of EDC grafts. The maximum ALT
level within the first 48 hours following liver transplant-
ation was chosen as a clinical marker of hepatic injury
and used to estimate the degree of IRI. Aminotransfer-
ases have been shown to be an appropriate marker of
hepatic IRI in a number of studies. Puhl et al. demon-
strated an inverse correlation between microcirculation,
a key factor in the development of IRI, and serum ALT/
AST levels in human liver transplantation [43]. More-
over, EDC organs, which are associated with increased
levels of IRI, display significantly elevated ALT/AST
levels [4]. In addition to assessing acute IRI, the TOP-
Study assesses graft survival during a 1-year follow-up
period. Although the impact of acute graft injury on
long-term survival is discussed controversially in the
literature, there is strong evidence that IRI correlates
significantly with long-term graft survival [44].
The tacrolimus concentration of 20 ng/ml was chosen
in the present trial based on safety data from previous
Table 3 Clinical studies of tacrolimus rinse in liver
transplantation
Author Number of
patients
Result P
Tacrolimus Placebo
St Peter et al., 2003 [21] 20 AST (IU/l) AST (IU/l) 0.02
day 1: 604 day 1: 1294
day 2: 683 day 2: 934
Kristo et al., 2011 [38] 26 ALT (IU/l) ALT (IU/l) 0.88
day 6: 79 day 6: 101
ALT, alanine transaminase; AST, aspartate transaminase.
Pratschke et al. Transplantation Research 2013, 2:3 Page 5 of 7
http://www.transplantationresearch.com/content/2/1/3studies [22,39]. At this dosage no adverse effects related
to the tacrolimus treatment have been reported. The
20 μg of tacrolimus dissolved in 1000 ml of Custodiol to
form the rinse solution represents a minute fraction of
the 1.75 ×10
3μg per day of tacrolimus administered
intravenously to a 70 kg adult. If even 80% of the tacroli-
mus in the rinse solution reached the systemic circula-
tion, the drug level would be below the detection limit
of 3 ng/ml. Therefore, the rinse solution seems to have
local effects in the liver graft, rather than contributing to
systemic immunosuppression.
In summary, a tacrolimus rinse could represent a new
strategy to reduce IRI and improve organ survival in
EDC organs in liver transplantation. A reduction of
organ damage in marginal grafts may allow the accept-
ance of more EDC organs, even in patients with high
MELD scores, thereby safely expanding the donor pool
in liver transplantation.
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